Intraovarian PRP for Low AMH: What the Research Shows

Intraovarian PRP — injection of platelet-rich plasma directly into the ovarian cortex — is one of the most actively discussed and most commercially marketed interventions in fertility medicine today. It is also one of the most frequently misrepresented, with some clinics offering it as a standard "ovarian rejuvenation" procedure with implied or explicit promises of significant reserve improvement that the current evidence does not fully support.

This article is a balanced, evidence-based assessment of what intraovarian PRP is, what the published research shows, who may genuinely benefit, and what the realistic expectations are — so that women with low AMH or premature ovarian insufficiency can make informed decisions rather than ones driven by hope and marketing.

The Scientific Rationale

The ovarian cortex contains primordial follicles — the resting egg pool that represents a woman's ovarian reserve. Standard IVF stimulation can only recruit follicles that have already begun their development toward ovulation (antral follicles). The primordial follicle pool itself — the much larger upstream reservoir — is normally not recruited.

The hypothesis behind intraovarian PRP is that the growth factors delivered by the platelet concentrate (VEGF, PDGF, EGF, TGF-β, IGF) may:

• Stimulate the activation of dormant primordial follicles into the growing pool
• Improve the local ovarian microenvironment — increasing vascularity, reducing inflammation, and supporting follicle survival
• In the context of the stem cell research discussed in P8-1 — potentially activate oogonial stem cells if present in the ovarian cortex

If even a fraction of the dormant primordial pool can be activated into antral follicles, women who previously showed no AFC on ultrasound and undetectable AMH might produce eggs that can be collected and fertilised.

What the Published Evidence Shows

The evidence for intraovarian PRP spans a range of study quality:

Supportive Evidence

• A 2016 case report by Sfakianoudis et al. (Greece) documented AMH improvement and IVF success in women with POI after intraovarian PRP — a widely cited early report that generated significant research interest.
• A 2019 prospective study from Greece reported measurable AMH increases in 11 of 27 women with POI after intraovarian PRP, with two clinical pregnancies.
• A 2021 retrospective series from China reported improvements in AFC and clinical pregnancy rates in women with poor ovarian response who received intraovarian PRP before IVF.
• Solo Clinic's own clinical experience — including the world's first stem cell-assisted conception at 45 — provides direct evidence that ovarian biological reactivation in women with severely compromised reserve is achievable in selected cases.

Important Limitations

• No large randomised controlled trials comparing intraovarian PRP to a control group exist yet. Most published data is from case series, retrospective reviews, or small prospective studies without control groups.
• Response rates vary widely across published series — from 30% to 70% showing any measurable AMH or AFC improvement. The proportion achieving a successful IVF cycle and live birth is smaller.
• The natural variability of AMH measurement (which can fluctuate by 20 to 30% between measurements) makes it difficult to distinguish genuine treatment response from normal biological variation in some cases.
• Selection bias is significant in published series — clinics report their successes; unreported negative results make the true response rate difficult to estimate.

Who May Benefit from Intraovarian PRP?

Based on current evidence, the women most likely to benefit from intraovarian PRP are:

• Women with severely diminished ovarian reserve (AMH below 0.5 ng/ml, AFC below 3) who have not responded to standard IVF stimulation
• Women with early premature ovarian insufficiency (POI) — particularly those with some residual ovarian biology (any detectable AMH, however low)
• Women who have had negative IVF cycles despite high-dose stimulation producing zero or only 1 to 2 eggs
• Women who are strongly committed to attempting conception with their own genetic material, are fully informed of the experimental nature of the procedure, and understand the comparison with donor egg IVF success rates

Women with complete POI — truly undetectable AMH and zero AFC on repeated assessment — have the lowest probability of response and should receive very honest counselling before committing to this intervention.

The Comparison That Must Be Part of Every Counselling Conversation

For women with severely diminished reserve, the alternative to intraovarian PRP is not "nothing" — it is donor egg IVF, which offers well-documented success rates of 55 to 65% per transfer at any recipient age. This comparison must be part of any counselling conversation about intraovarian PRP. A woman choosing to pursue intraovarian PRP rather than donor egg IVF is making a choice between a potentially meaningful but uncertain experimental intervention and a well-established, high-probability alternative — and she deserves complete information about both options.

At Solo Clinic, this conversation is a mandatory part of the intraovarian PRP assessment — not an afterthought.

The Procedure

Intraovarian PRP is performed transvaginally under ultrasound guidance, typically under sedation or light anaesthesia:

• Blood is drawn and centrifuged to produce PRP
• A fine needle is guided transvaginally into each ovary under ultrasound
• PRP is injected into the ovarian cortex (typically 1 to 2 ml per ovary)
• Recovery is 1 to 2 hours; mild ovarian discomfort for 24 to 48 hours is normal
• AMH and AFC are reassessed at 1, 2, and 3 months post-procedure to detect any response
• If response occurs (rising AMH, new antral follicles), IVF stimulation is planned

Frequently Asked Questions

Q1. How likely is intraovarian PRP to raise my AMH?

Based on available published data, approximately 40 to 60% of women with severely diminished reserve show some measurable AMH or AFC improvement after intraovarian PRP. Of those who respond, the proportion who go on to complete a successful IVF cycle and achieve a live birth is smaller — precise figures vary by series and patient selection. Realistic pre-procedure counselling from your team, based on your specific clinical picture, is the most reliable guide.

Q2. Can I have intraovarian PRP and donor egg IVF at the same time?

In principle, yes — some women pursue intraovarian PRP while also beginning the process of donor egg IVF workup, keeping both pathways open simultaneously. This approach avoids the delay of waiting 3 months for PRP response assessment before starting the donor egg process if PRP does not produce a response. Discuss this parallel approach with your clinical team.

Q3. How much does intraovarian PRP cost in India?

Costs vary by centre. In established fertility clinics in Pune, intraovarian PRP procedure costs range from approximately INR 25,000 to INR 60,000, not including the subsequent monitoring and IVF cycle costs. A complete cost estimate in writing, before committing, is essential. Compare this total investment against the probability of achieving a live birth from this pathway versus donor egg IVF.